Human Anti-CD40 Recombinant Antibody (clone 3.1.1) (CAT#: HPAB-1833-FY)

Figure 1 CH1-hinge basis of agonistically inactive IgG3 and superior IgG2.

Representative FACS profile showing the percentage of OT-I cells (CD45.1+TCRVα2+) among CD8+ T cells in human CD40/FcγR-transgenic mice treated and analyzed together with control or anti-human CD40 antibodies of indicated clones (Clones 21.4.1 and 3.1.1 have been described in Patent No.:US 7,338,660; Clone 21.4.1 in the IgG2 form is also known as CP-870,893) and constant domains (30 μg per mouse).

Liu, X., Zhao, Y., Shi, H., Zhang, Y., Yin, X., Liu, M., ... & Li, F. (2019). Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nature communications, 10(1), 1-15.

Figure 2 CH1-hinge basis of agonistically inactive IgG3 and superior IgG2.

Representative quantification showing the percentage of OT-I cells (CD45.1+TCRVα2+) among CD8+ T cells in human CD40/FcγR-transgenic mice treated and analyzed together with control or anti-human CD40 antibodies of indicated clones (Clones 3.1.1) and constant domains (30 μg per mouse).

Liu, X., Zhao, Y., Shi, H., Zhang, Y., Yin, X., Liu, M., ... & Li, F. (2019). Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nature communications, 10(1), 1-15.

Figure 3 Shows inhibition in the growth of CD40 negative K562 tumors in SCID mice by different concentrations of anti-CD40 agonist mAb 3.1.1.

Figure 4 Shows inhibition in the growth of BT 474 breast cancer cells in SCID-beige mice by anti-CD40 agonist antibodies.